Trials / Unknown
UnknownNCT04395742
1,3,7-Trimethylxanthine as a Treatment of COVID-19: Results of a Controlled Study
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 93 (estimated)
- Sponsor
- Poitiers University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- —
Summary
This is observational study to assess the prognosis of patients hospitalized with COVID-19 confirmed by RT-PCR and exposed to trimethylxanthine (TMX). Trimethylxanthine is the active molecule present in coffee. Due to the lack of etiologic treatments and considering interest about old treatments as an avenue for research, we conducted a comparative study aiming to evaluate the effect of 1,3,7-trimethylxanthine on COVID-19 infected patients. This is actually a study about methodology. The objective of this study is therefore not to demonstrate the effect of the substance on the disease but the importance of a rigorous methodology in scientific research. This project is called "Method and Teaching of Scientific Studies".
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Data collection | Only data collection |
Timeline
- Start date
- 2020-05-01
- Primary completion
- 2020-12-01
- Completion
- 2020-12-01
- First posted
- 2020-05-20
- Last updated
- 2020-05-20
Source: ClinicalTrials.gov record NCT04395742. Inclusion in this directory is not an endorsement.